Naveen Mansukhani, director of operations and account management of Retail Pharmacy Services at Cardinal Health, talks about how the responsibility for saving costs does not just fall on one department or person, but is collaborative and requires strategy.
Reducing costs falls on multiple health care departments, and the help of data, analytics, and specialty pharmacy strategies can ensure that cost reduction is successful, says Naveen Mansukhani, director of operations and account management of Retail Pharmacy Services at Cardinal Health.
Transcript
What strategies are health systems employing to combat the increasing costs of specialty drugs within their specialty pharmacy programs?
It's really about employing a collaborative approach. It's not just a pharmacy problem of controlling costs. It's also patient navigators, the pharmacy department, the billing department, ensuring that things are getting built properly before it's administered to a patient, where it ends up being a cost to the hospital.
How are health systems leveraging data and analytics to identify cost-saving opportunities and make informed decisions regarding specialty drug pricing and procurement?
This iswhere the importance of a specialty GPO [group purchasing organizations] comes into play. Specialty GPOs can help with these data analytics and ensure that the hospitals are buying the best possible drug at the least possible cost.
Are there any best practices or success stories of health system specialty pharmacy strategies that have effectively tackled the challenge of escalating specialty drug costs?
There's many hospitals that have employed strategies that, really from a retail perspective, of getting specialty drugs into the community. So, from hospital into community of ordering these drugs, and now they become a revenue to the hospital versus just simply a cost. That's where a specialty pharmacy strategy really makes sense, and where hospitals are finding success. It also helps with the patient end to end approach where the hospital is able to work with patients on the outside when they become outpatients. It improves compliance, It improves outcomes, and it controls overall health care costs.
AstraZeneca joins efforts to address high drug prices by capping out-of-pocket costs for its inhalers; Opill, the first OTC birth control pill, is now accessible through online sales; expansion prompts questions on the effectiveness and regulation of remote monitoring technology.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
6 Blood Biomarkers Identified to Predict CVD Risk in Patients With Rheumatoid Arthritis
March 15th 2024Baseline levels of serum amyloid A, C‐reactive protein, soluble tumor necrosis factor receptor 1, adiponectin, YKL‐40, and osteoprotegerin could be used to predict a rise in arterial inflammation.
Read More
AstraZeneca joins efforts to address high drug prices by capping out-of-pocket costs for its inhalers; Opill, the first OTC birth control pill, is now accessible through online sales; expansion prompts questions on the effectiveness and regulation of remote monitoring technology.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
6 Blood Biomarkers Identified to Predict CVD Risk in Patients With Rheumatoid Arthritis
March 15th 2024Baseline levels of serum amyloid A, C‐reactive protein, soluble tumor necrosis factor receptor 1, adiponectin, YKL‐40, and osteoprotegerin could be used to predict a rise in arterial inflammation.
Read More
2 Commerce Drive
Cranbury, NJ 08512